trimetrexate has been researched along with Carcinoma, Epidermoid in 8 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimetrexate (TMQ) is a synthetic folate antagonist that has demonstrated non-cross resistance with methotrexate in preclinical screens." | 2.68 | Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study. ( Brown, TD; Fleming, TR; Macdonald, JS; Ross, SW, 1996) |
| "Human SCC-25 squamous carcinoma cells were exposed to methotrexate, trimetrexate or PT523 at a concentration of 5 microM for 24 h along with various concentrations of etoposide or novobiocin during the final 2 h." | 1.29 | Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. ( Holden, SA; Northey, D; Robinson, MF; Rosowsky, A; Teicher, BA, 1995) |
| "Three human squamous carcinoma cell lines (FaDu, A253, and SQCC/Y1) were tested for sensitivity to methotrexate (MTX) and trimetrexate, a second generation folate antagonist in clinical trials." | 1.28 | Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug. ( Bertino, JR; Chang, YM; McGuire, JJ; Pizzorno, G, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 6 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holden, SA | 1 |
| Teicher, BA | 1 |
| Robinson, MF | 1 |
| Northey, D | 1 |
| Rosowsky, A | 1 |
| Fleming, TR | 1 |
| Brown, TD | 2 |
| Ross, SW | 1 |
| Macdonald, JS | 1 |
| Faessel, HM | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Greco, WR | 1 |
| Falkson, G | 2 |
| Ryan, LM | 1 |
| Haller, DG | 1 |
| Weiss, GR | 1 |
| Liu, PY | 1 |
| O'Sullivan, J | 1 |
| Alberts, DS | 1 |
| Neefe, JR | 1 |
| Hutchins, LF | 1 |
| van der Laan, BF | 1 |
| Jansen, G | 1 |
| Kathmann, I | 1 |
| Schornagel, JH | 1 |
| Hordijk, GJ | 1 |
| Pizzorno, G | 1 |
| Chang, YM | 1 |
| McGuire, JJ | 1 |
| Bertino, JR | 1 |
| Alberts, AS | 1 |
| Badata, M | 1 |
| Terblanche, AP | 1 |
| Schmid, EU | 1 |
3 trials available for trimetrexate and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Phase II trial of trimetrexate in advanced esophageal cancer: a southwest oncology group study.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal | 1996 |
Phase II trial for the evaluation of trimetrexate in patients with inoperable squamous carcinoma of the esophagus.
Topics: Aged; Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Female; Humans; Male; Middle | 1992 |
A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Depsipeptides; Female; Humans; Neoplasm Recurrence, | 1992 |
5 other studies available for trimetrexate and Carcinoma, Epidermoid
| Article | Year |
|---|---|
Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cell Line; Cell Survival; D | 1995 |
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; D | 1999 |
Mechanisms of acquired resistance to methotrexate in a human squamous carcinoma cell line of the head and neck, exposed to different treatment schedules.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line; Cell Survival; Drug Resistance; Head and | 1991 |
Inherent resistance of human squamous carcinoma cell lines to methotrexate as a result of decreased polyglutamylation of this drug.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance; Head and Neck Neoplasms; Humans; M | 1989 |
Trimetrexate in advanced carcinoma of the esophagus.
Topics: Carcinoma, Squamous Cell; Drug Evaluation; Esophageal Neoplasms; Humans; Quinazolines; Trimetrexate | 1988 |